Zai Lab Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $25.5950
- Today's High:
- $28.3900
- Open Price:
- $26.0000
- 52W Low:
- $20.98
- 52W High:
- $102.43
- Prev. Close:
- $25.0200
- Volume:
- 947926
Company Statistics
- Market Cap.:
- $2.686 billion
- Book Value:
- 12.65
- Revenue TTM:
- $0.182 billion
- Operating Margin TTM:
- -264%
- Gross Profit TTM:
- $-0.481 billion
- Gross Profit TTM:
- $-0.481 billion
- Profit Margin:
- -290.1%
- Return on Assets TTM:
- -18.1%
- Return on Equity TTM:
- -36.7%
Company Profile
Zai Lab Ltd had its IPO on 2017-09-20 under the ticker symbol ZLAB.
The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Zai Lab Ltd has a staff strength of 0 employees.
Stock update
Shares of Zai Lab Ltd opened at $26 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $25.6 - $28.39, and closed at $27.43.
This is a +9.63% increase from the previous day's closing price.
A total volume of 947,926 shares were traded at the close of the day’s session.
In the last one week, shares of Zai Lab Ltd have increased by +14.29%.
Zai Lab Ltd's Key Ratios
Zai Lab Ltd has a market cap of $2.686 billion, indicating a price to book ratio of 1.8 and a price to sales ratio of 14.74.
In the last 12-months Zai Lab Ltd’s revenue was $0.182 billion with a gross profit of $-0.481 billion and an EBITDA of $-0.473 billion. The EBITDA ratio measures Zai Lab Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Zai Lab Ltd’s operating margin was -264% while its return on assets stood at -18.1% with a return of equity of -36.7%.
In Q2, Zai Lab Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 30.4%.
Zai Lab Ltd’s PE and PEG Ratio
- Forward PE
- -
- Trailing PE
- -
- PEG
- None
Its diluted EPS in the last 12-months stands at $-5.84 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zai Lab Ltd’s profitability.
Zai Lab Ltd stock is trading at a EV to sales ratio of 5.59 and a EV to EBITDA ratio of -2.137. Its price to sales ratio in the trailing 12-months stood at 14.74.
Zai Lab Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
Zai Lab Ltd ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
Zai Lab Ltd ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
Zai Lab Ltd’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, Zai Lab Ltd's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, Zai Lab Ltd paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $27.43
- 52-Week High
- $102.43
- 52-Week Low
- $20.98
- Analyst Target Price
- $92.02
Zai Lab Ltd stock is currently trading at $27.43 per share. It touched a 52-week high of $102.43 and a 52-week low of $102.43. Analysts tracking the stock have a 12-month average target price of $92.02.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Zai Lab Ltd
Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)
Most Active
Top Gainers
Top Losers
About
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.